Vaccines Respiratory

COVID Vaccine Sales, 2023 to 2025

Pfizer-booked Comirnaty and Moderna COVID product sales. The APA world became a seasonal market in two years.

Adult RSV Vaccine Sales, 2023 to 2025

Arexvy vs Abrysvo vs mRESVIA. ACIP made adult RSV a single dose, not an annual franchise. GBP converted at that year's IRS average.

Infant RSV Prevention: Beyfortus Sales

The disclosed infant RSV P&L is a monoclonal antibody, not a vaccine. Maternal Abrysvo is not split out; Merck Enflonsia launched June 2025 without a franchise line.

Flu Franchise Sales, 2025

Sanofi flu/COVID bundle, Seqirus Fluad and Flucelvax (FY June 2025), GSK influenza, and Moderna mFLUSIVA at zero 2025 sales. Not like-for-like periods.

COVID plus Flu Combo Pipeline

Who can sell a single-injection respiratory franchise. RSV stays a separate ACIP product in 2026.

ProgramCompanyComponentsStatusNote
mCOMBRIAX (mRNA-1083)ModernaCOVID + fluEU-approved; US path follows mFLUSIVASingle-injection respiratory franchise. US timing depends on flu label plus combination data.
mFLUSIVA (mRNA-1010)ModernaFlu onlyFDA 5 Aug 2026, adults 50+First US mRNA flu shot. Traditional approval 50-64; accelerated 65+. ACIP still the demand switch.
Pfizer/BioNTech flu + COVIDPfizer / BioNTechCOVID + fluIn developmentDefends the Comirnaty seasonal slot with one injection.
Sanofi + Novavax NuvaxovidSanofi / NovavaxCOVID protein; flu separateNuvaxovid in selected Sanofi marketsNot a single-shot combo. Sanofi leads selected-market COVID commercial.
Arexvy / Abrysvo / mRESVIAGSK / Pfizer / ModernaRSV onlyApproved; not annualNo commercial COVID+flu+RSV triple in 2026. RSV remains a separate visit.

ACIP RSV Recommendation Path

Arexvy sales were £1,238m in 2023, £590m in 2024 and £593m in 2025 (GSK). Shared clinical decision-making in 2023, then single-dose 75+ in 2024.

May 2023
ApprovalGSK / Pfizer

FDA approves Arexvy (3 May 2023) and adult Abrysvo (31 May 2023)

The first two US RSV vaccines, both for adults 60 and older.

Jun 2023
ACIPCDC ACIP

ACIP: shared clinical decision-making on a single dose for adults 60+ (21 Jun 2023)

First recommendation is optional, not routine.

Aug 2023
ApprovalPfizer

FDA approves maternal Abrysvo (21 Aug 2023)

Opens a pregnancy indication that protects infants from birth through 6 months. A different group from Arexvy's older-adult slot.

May 2024
ApprovalModerna

FDA approves mRESVIA (31 May 2024)

Third US RSV vaccine. Share fight, not a new TAM.

Jun 2024
ACIPCDC ACIP

ACIP: single dose for all adults 75+ and for adults 60-74 at increased risk

The load-bearing vote. Single dose, age-gated. Arexvy sales fell from £1,238m (2023) to £590m (2024); GSK cites a more limited ACIP recommendation and channel inventory consumption after launch-year stocking.

Apr 2025
ACIPCDC ACIP

ACIP adds 50-59 at increased risk (vote 16 Apr 2025)

Widens eligibility; still a single dose. Not confirmed in a primary source as of 2026-10-31: CDC adoption on 25 Jun 2025.

Jun 2025
ApprovalMerck

FDA approves Enflonsia (clesrovimab) on 9 Jun 2025

Second infant mAb. Infant prevention is now antibodies (Beyfortus, Enflonsia) plus maternal Abrysvo.

US Adult Respiratory Coverage, 2025-26 Season

CDC NIS-FRVM as of 22 Feb 2026. Flu and COVID are this-season coverage. RSV is ever received a dose.

Ask Sterling

Register for a premium account to gain access to Sterling AI.

Get Started

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving EV industry growth?
Menu
Favorites
Vaccines Respiratory: Market Data | Sterling